Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 in Advanced Solid Tumors
NCT05114759Phase 1Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of ruzaltatug rezetecan in solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
ruzaltatug rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05114759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114759.